ChemicalBook > CAS DataBase List > Lodelcizumab
Lodelcizumab
- Product Name
- Lodelcizumab
- CAS No.
- 1355338-54-3
- Chemical Name
- Lodelcizumab
- Synonyms
- Lodelcizumab;Lodelcizumab (anti-PCSK9);Research Grade Lodelcizumab;Research Grade Lodelcizumab(DHJ24005)
- CBNumber
- CB08080882
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Lodelcizumab Chemical Properties,Usage,Production
Uses
Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia[1].
References
[1] Pordy, et al. Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis. Patent. WO2017031151 A1.
Lodelcizumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Lodelcizumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
1355338-54-3, LodelcizumabRelated Search:
TocilizuMab
Meplazumab
mepolizumab
Refanezumab
Onvatilimab
Toripalimab
Nipocalimab
MilatuzuMab
Bemarituzumab
Brentuximab